




Go Further Program-Wide Highlights

Fiscal Year	Funding Amount	Cervical Cancer Screening Target
FY19	\$30,600,419	463,012
FY20	\$22,994,705	912,749
FY21	\$39,673,711	2,004,598
FY22	\$36,693,109	2,147,323
FY23	\$38,946,400*	1,780,964

*Pending Congressional notification and approval



* Services start in fiscal year 2021
 ** Not a Go Further target country but contributes to cervical cancer results through other PEPFAR programming


Cervical cancer is the number one cancer killer of women in sub-Saharan Africa, with roughly 110,000 women diagnosed annually; of these women, about 66% will die from the disease. Women living with HIV (WLHIV) are up to six times more likely to develop persistent precancerous lesions and progress to cervical cancer, often with more aggressive forms and higher mortality.

Launched in May 2018 to address this challenge, Go Further is an innovative public-private partnership between the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), the George W. Bush Institute, the Joint United Nations Programme on HIV/AIDS (UNAIDS), Merck, and Roche. The partnership collaborates closely with governments to strategize on ways to provide services for women from prevention through the cancer journey. Go Further began working in eight countries (Botswana, Eswatini, Lesotho, Malawi, Mozambique, Namibia, Zambia, and Zimbabwe), and expanded services to four additional countries (Ethiopia, Kenya, Tanzania, Uganda) in fiscal year (FY) 2021. The objectives are to screen all WLHIV on ART between the ages of 25 and 49 for cervical cancer, and to treat pre-invasive cervical cancer lesions to prevent progression to cervical cancer.


Global Context

Women Aged 15+ at Risk of Developing Cervical Cancer (HPV Information Centre)	2.869 Billion
Cervical Cancer Incidence (Age-Standardized Rate Per 100,000) (IARC/GLOBOCAN)	13.3
Annual Number of New Cervical Cancer Cases (IARC/GLOBOCAN)	604,127
Annual Number of Cervical Cancer Deaths (IARC/GLOBOCAN)	341,831
Standardized Mortality Rate Per 100,000 (IARC/GLOBOCAN)	7.3
Total Number of Women, All Ages, on ART (PEPFAR FY22 Q2)	11,728,519


Cervical Cancer Screening Scale Up, FY18-FY22 Q2, All Countries Reporting




Cervical Cancer Cascade, FY18-FY22 Q2, All Countries Reporting



Screenings by Age FY18-FY22 Q2, All Countries Reporting



Treatment Rate by Period, All Countries Reporting



RESULTS SUMMARY

- ◆ Since program reporting began in FY18, 4,498,310 cervical cancer screenings have been conducted.
- ◆ Of these, 3,704,947 (82%) were reported as first-time screenings, 66,204 (1%) were follow-up screens, and 727,159 (16%) were re-screens.
- ◆ 169,017 treatments for precancerous lesions have been performed for an overall treatment rate of 74%.

